Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.80B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 0.57M
Average 0.71M
ZYME Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Zymeworks Inc.NASDAQ: ZYME
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income turns positive
Q3 FY2026 operating income was $177.6M, compared with -$22.11M a year earlier. Trailing-twelve-month operating income was $44.15M.
Context
- Operating income amounted to 87.3% of revenue in FY2025, down 92.4 pp from a year earlier.
- Operating income increased in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 8 analysts of $133.24M (+244.0%) for the fiscal year ending Dec 2026, a step up from the +32.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $177.6M+521.0% QoQ
- Last fiscal yearDec 2025
- -$92.54M+32.5% YoY
- LTMSep 2026
- $44.15M+162.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +903.2% | -48.9% | -952.2 pp |
| 1 year | +32.5% | +244.0% | +211.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (92.54M) USD
- Year-over-year change
- +32.5%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (92.54M) | +32.5% |
| FY2024 | 2024-12-31 | (137.11M) | +0.7% |
| FY2023 | 2023-12-31 | (138.05M) | -205.8% |
| FY2022 | 2022-12-31 | 130.53M | +160.5% |
| FY2021 | 2021-12-31 | (215.63M) | — |
Operating Income vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 operating income of $44.15M is the 2nd highest of the 11 companies compared; the peer median is -$104.83M.
- Its year-over-year change of +162.5% is the 3rd highest of 11, against a peer median of -11.4%.
- Operating income amounts to 16.6% of revenue for ZYME, versus a peer median of 165.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $289.66M | +208.4% | — | 41.3% | |
| LTM Sep 2026 | $44.15M | +162.5% | — | 16.6% | |
| LTM Mar 2026 | $30.7M | +307.5% | — | 42.3% | |
| LTM Mar 2026 | -$63.66M | +36.0% | — | 40.5% | |
| LTM Mar 2026 | -$64.66M | -279.8% | — | 181.9% | |
| LTM Mar 2026 | -$91.17M | +33.2% | — | — | |
| LTM Mar 2026 | -$118.48M | +5.6% | — | 149.6% | |
| LTM Mar 2026 | -$163.14M | -207.8% | — | 1372.9% | |
| LTM Jun 2026 | -$216.08M | -69.5% | — | 205.8% | |
| LTM Sep 2026 | -$300.69M | -28.4% | — | — | |
| LTM Sep 2026 | -$334.5M | -30.5% | — | 298657.1% | |
| Peer median (excluding ZYME) | -$104.83M | -11.4% | — | 165.8% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| Weighted Avg Shares | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Weighted Avg Shares (Diluted) | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$25.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.